The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
Status:
RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and efficacy of Pyrotinib at different doses in combination with trastuzumab and paclitaxel chemotherapy for first-line treatment of HER2-positive advanced breast cancer.
Phase:
PHASE1
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborators:
Affiliated Hospital of Jiangsu University Affiliated Hospital of Nantong University Shuyang County Traditional Chinese Medicine Hospital The Affiliated Hospital of Xuzhou Medical University The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China The First People's Hospital of Xuzhou The Second People's Hospital of Changshu